Cocktails in the World of IBD
Going out for drinks with friends may be good for the soul, but it will, most likely, do nothing to improve IBD symptoms. Enter the new meaning of the word cocktail, the kind that scientists and innovators are creating and which may very likely be the wave of future treatments of IBD and other chronic diseases. One exciting example of such a cocktail is BX003 by BiomX.
Research has shown that a prevalence of Klebsiella pneumoniae, also known as K. pneumoniae, is thought to be the culprit in the inflammation and “leaky gut” associated with IBD. Bacteriophages, or phages for short, are viruses that can infect and kill bacterial cells, and there are a variety of types of phages. BX003 is an orally-administered cocktail made up of a specific mix of phages that attack the K. pneumoniae, which are overly present in the gut of IBD patients.
After the 2021 report of a successful Phase 1 first-in-human clinical trial, BiomX has entered a Phase 1b/2a study with results expected in late 2023. This is promising news since BiomX refers to statistics demonstrating that the issue with biological therapies and immunosuppressants is the response rate of only 40-60% as well as the risk of patients becoming refractory to such treatments. By creating the proper microbiome in the gut, this type of cocktail could arguably be considered regenerative medicine as it teaches the body to heal.